The teratogenicity of the newer antiepileptic drugs - an update

Citations Over TimeTop 1% of 2014 papers

Abstract

Objective To assess the risk of teratogenicity from maternal intake of the more widely used newer antiepileptic drugs, especially lamotrigine, levetiracetam and topiramate. Materials and methods Use of confidence interval and regression methods to compare risks of foetal malformation in pregnancies in women exposed (n = 1572) and in women with epilepsy not exposed (n = 153) to antiepileptic drugs in the first trimester. Results Compared with the foetal malformation rate in women with epilepsy who were untreated in the first trimester (3.3%), the malformation rates for lamotrigine (4.6%), levetiracetam (2.4%) and topiramate (2.4%), all in monotherapy, were not statistically significantly different. However, the malformation rates for topiramate as part of polytherapy (14.1%) and for valproate in both monotherapy (13.8%) and polytherapy (10.2%) were statistically significantly higher. Regression analysis of combined monotherapy and polytherapy data showed no statistically significant increased risk of teratogenesis associated with lamotrigine or levetiracetam, but a statistically significant and dose-related risk for first trimester topiramate (P = 0.01) and valproate (P < 0.0001) exposure. Conclusions Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be.

Related Papers

• → Newer anticonvulsants: Lamotrigine, topiramate and gabapentin(2012)63 cited
• → Subjective preference for lamotrigine or topiramate in healthy volunteers: Relationship to cognitive and behavioral functioning(2005)17 cited
• → Adverse reactions of Topiramate and Lamotrigine in children(2004)16 cited
• → Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life(2002)17 cited
• Forms of focal epilepsy in children and their treatment with antiepileptic drug of different generations(2011)